Sensitivity analysis (LOCF) supports improvement in PFWD with canakinumab treatment. LC means (80% CI) of placebo-adjusted change from baseline in maximum 6MWT distance are presented with the LOCF for any missing data.
*p < 0.05 versus placebo.
LC, least-squares; LOCF, last observation carried forward; PFWD, pain-free walking distance; 6MWT, 6-minute walk test.